Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

Clinics in Liver Disease

Volumn 22, Issue 1, 2018, Pages 175-187

  Hung, Chun Kit ^a   Bodenheimer, Henry C ^a  

^a Northwell Health ^*  (United States)

Author keywords

NAFLD; NASH; Pharmacotherapy; Treatment

Indexed keywords

ALPHA TOCOPHEROL; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PHOSPHOLIPID; PIOGLITAZONE; PLACEBO; POLYUNSATURATED FATTY ACID; PROBIOTIC AGENT; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

BARIATRIC SURGERY; CALORIC RESTRICTION; COFFEE; DIET SUPPLEMENTATION; ENDOSCOPIC SURGERY; EXERCISE; HUMAN; LIFESTYLE MODIFICATION; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROUX-EN-Y GASTRIC BYPASS; SIDE EFFECT; SILYBUM MARIANUM; WEIGHT REDUCTION; BODY WEIGHT LOSS; DIET; DIETARY SUPPLEMENT; LIFESTYLE;

BARIATRIC SURGERY; DIET; DIETARY SUPPLEMENTS; EXERCISE; HUMANS; LIFE STYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; THIAZOLIDINEDIONES; WEIGHT LOSS;

EID: 85031115083     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2017.08.012     Document Type: Review

References (85)

1. Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Disease, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
2. Patel, N.S., Doycheva, I., Peterson, M.R., et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 13:3 (2015), 561–568.
3. Wong, V.W., Chan, R.S., Wong, G.L., et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 59:3 (2013), 536–542.
4. Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:6 (2005), 1313–1321.
5. Promrat, K., Kleiner, D.E., Niemeier, H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51 (2010), 121–129.
6. Musso, G., Cassader, M., Rosina, F., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55:4 (2012), 885–904.
7. Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149 (2015), 367–378.
8. Johnson, N.A., Sachinwalla, T., Walton, D.W., et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 50 (2009), 1105–1112.
9. Perseghin, G., Lattuada, G., De Cobelli, F., et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 30 (2007), 683–688.
10. George, St., Bauman, A., Johnston, A., et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 50 (2009), 68–76.
11. Hallsworth, K., Fattakhova, G., Hollingsworth, K.G., et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 60 (2011), 1278–1283.
12. Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 47:5 (2007), 711–717.
13. Musso, G., Gambino, R., De Michieli, F., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37:4 (2003), 909–916.
14. Enjoji, M., Yasutake, K., Kohjima, M., et al. Nutrition and nonalcoholic fatty liver disease: the significance of cholesterol. Int J Hepatol, 2012, 2012, 925807.
15. Yasutake, K., Nakamuta, M., Shima, Y., et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 44 (2009), 471–477.
16. Machado, R.M., Stefano, J.T., Oliveira, C.P., et al. Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content. J Nutr 140:6 (2010), 1127–1132.
17. Tetri, L.H., Basaranoglu, M., Brunt, E.M., et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295 (2008), G987–G995.
18. Hussein, O., Grosovski, M., Lasri, E., et al. Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. World J Gastroenterol 13 (2007), 361–368.
19. Tanaka, N., Sano, K., Horiuchi, A., et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 42:4 (2008), 413–418.
20. Capanni, M., Calella, F., Biagini, M.R., et al. Prolonged n-3polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 23:8 (2006), 1143–1151.
21. Argo, C.K., Patrie, J.T., Lackner, C., et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J Hepatol 62:1 (2015), 190–197.
22. Desarathy, S., Dasarathy, J., Khiyami, A., et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 49:2 (2015), 137–144.
23. Alwahsh, S.M., Gebhardt, R., Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Arch Toxicol 91:4 (2017), 1545–1563.
24. Abdelmalek, M.F., Suzuki, A., Guy, C., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51:6 (2010), 1961–1971.
25. Abid, A., Taha, O., Nseir, W., et al. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 51:5 (2009), 918–924.
26. Assy, N., Nasser, G., Kamayse, I., et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol 22:10 (2008), 811–816.
27. Chun, M., Ma, J., Patel, K., et al. Fructose, high-fructose corn syrup, sucrose and non-alcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 100 (2014), 833–849.
28. Hannah, W.N. Jr., Harrison, S.A., Effect of weight loss, diet, exercise and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis 20:2 (2016), 339–350.
29. Tendler, D., Lin, S., Vancy, W.S. Jr., et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 52 (2007), 589–593.
30. Haufe, S., Engeli, S., Kast, P., et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 53:5 (2011), 1504–1514.
31. Marchesini, G., Petta, S., Dalle Grave, R., Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice. Hepatology 63:6 (2016), 2032–2043.
32. Thomas, C., Day, C.P., Trenell, M.I., Lifstyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. Hepatology 56:1 (2012), 255–266.
33. Ong, J.P., Elariny, H., Collantes, R., et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 15:3 (2005), 310–315.
34. Zelber-Sagi, S., Shoham, D., Zvibel, I., et al. Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol 9:2 (2017), 91–98.
35. Raynor, H.A., Champagne, C.M., Position of the academy of nutrition and dietetics: interventions for the treatment of overweight and obesity in adults. J Acad Nutr Diet 116:1 (2016), 129–147.
36. Pimentel, C.F.M.G., Lai, M., Nitrition interventions for chronic liver diseases and nonalcoholic fatty liver disease. Med Clin North Am 100 (2016), 1303–1327.
37. Buchwald, H., Avidor, Y., Braunwald, E., Bariatric surgery: a systematic review and meta-analysis. JAMA 291:14 (2004), 1724–1737.
38. Mechanick, J.L., Youdim, A., Jones, D.B., et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring) 21:Suppl1 (2013), S1–S27.
39. Buchwald, H., Oien, D.M., Metabolic/bariatric surgery worldwide 2011. Metabolic/bariatric surgery worldwide 2011. Obes Surg 23:4 (2013), 427–436.
40. Mattar, S.G., Velcu, L.M., Rabinovitz, M., et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242:4 (2005), 610–617.
41. Bower, G., Toma, T., Harling, L., et al. Bariatric surgery and non-alcoholic fatty liver disease: a systemic review of liver biochemistry and histology. Obes Surg 25 (2015), 2280–2289.
42. Longitudinal assessment of bariatric surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 361 (2009), 445–454.
43. Adams, T.D., Gress, R.E., Smith, S.C., et al. Long-term mortality after gastric bypass surgery. N Engl J Med 357:8 (2007), 753–761.
44. Burza, M.A., Romero, S., Kotronen, A., et al. Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study. PLoS One, 8(3), 2013, e60495.
45. Mathurin, P., Hollebecque, A., Arnalsteen, L., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137:2 (2009), 532–540.
46. Bower, G., Athanasiou, T., Isla, A.M., et al. Bariatric surgery and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 27:7 (2015), 755–768.
47. Kral, J.G., Thung, S.N., Biron, S., et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135:1 (2004), 48–58.
48. Abu Dayyeh, B.K., Thompson, C.C., Obesity and bariatrics for the endoscopist: new techniques. Therap Adv Gastroenterol 4:6 (2011), 433–442.
49. Choi, H.S., Chun, H.J., Recent trends in endoscopic bariatric therapies. Clin Endosc 50:1 (2017), 11–16.
50. Ricci, G., Bersani, G., Rossi, A., et al. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg 18:11 (2008), 1438–1442.
51. De Jonge, C., rensen, S.S., Koek, G.H., et al. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 11:11 (2013), 1517–1520.
52. Popov, V.B., Thompson, C.C., Kumar, N., et al. Effect of intragastric balloons on liver enzymes: a systemic review and meta-analysis. Dig Dis Sci 61:9 (2016), 2477–2487.
53. Lee, Y.M., Low, H.C., Lim, L.G., et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc 76:4 (2012), 756–760.
54. Sokol, R.J., McKim, J.M. Jr., Goff, M.C., et al. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 114 (1998), 164–174.
55. Morante, M., Sandoval, J., Gomez-Cabrea, M.C., et al. Vitamin E deficiency induces liver nuclear factor-κB DNA binding activity and changes in related genes. Free Radic Res 39:10 (2005), 1127–1138.
56. Sanyal, A.J., Chalasani, N., Kowdley, K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:18 (2010), 1675–1685.
57. Lavine, J.E., Schwimmer, J.B., Van Natta, M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents. JAMA 305:16 (2011), 1659–1668.
58. Bjelakovic, G., Nikolova, D., Gluud, L.L., et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297 (2007), 842–857.
59. SchÜrks, M., Glynn, R.J., Rist, P.M., et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomized controlled trials. BMJ, 341, 2010, c5702.
60. Klein, E.A., Thompson, I.M. Jr., Tangen, C.M., et al. Vitamin E and the risk of prostate cancer. The Selenium and vitamin E cancer prevention trial (SELECT). JAMA 306 (2011), 1549–1556.
61. Hossain, N., Kanwar, P., Mohanty, S.R., A comprehensive updated review of pharmaceutical and nonpharmaceutical treatment for NAFLD. Gastroenterol Res Pract, 2016, 2016, 7109270.
62. Loguercio, C., Andreone, P., Brisc, C., et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med 52:9 (2012), 1658–1665.
63. Hannah, W.N. Jr., Harrison, S.A., Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Dig Dis Sci 61 (2016), 1365–1374.
64. Gutierrez-Grobe, Y., Chavez-Tapia, N., Sanchez-Valle, V., et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Hepatol 11 (2012), 350–355.
65. Zelber-Sagi, S., Salomone, F., Webb, M., et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res 165 (2015), 428–436.
66. Graeter, T., Niedermayer, P.C., Mason, R.A., et al. Coffee consumption and NAFLD: a community based study on 1223 subjects. BMC Res Notes, 8, 2015, 640.
67. Molloy, J.W., Calcagno, C.J., Williams, C.D., et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55:2 (2012), 429–436.
68. Eslamparast, T., Poustchi, H., Zamani, F., et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 99 (2014), 535–542.
69. Alisi, A., Bedogni, G., Baviera, G., et al. Randomized clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 39 (2014), 1276–1285.
70. Wong, V.W., Won, G.L., Chim, A.M., et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 12 (2013), 256–262.
71. Ratziu, V., Goodman, Z., Sanyal, A., Current efforts and trends in the treatment of NASH. Hepatol 62 (2015), S65–S75.
72. Lutchman, G., Modi, A., Kleiner, D.E., et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 51 (2010), 445–453.
73. Ratziu, V., Charlotte, F., Bernhardt, C., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51 (2010), 445–453.
74. Levin, D., Bell, S., Sund, R., et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58 (2015), 493–504.
75. Haukeland, J.W., Konopski, Z., Eggesbo, H.B., et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44:7 (2009), 853–860.
76. Loomba, R., Lutchman, G., Kleiner, D.E., et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 29:2 (2009), 172–182.
77. Rakoski, M.O., Singal, A.G., Rogers, M.A., et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 32:10 (2010), 1211–1221.
78. Zelber-Sagi, S., Kessler, A., Brazowsky, E., et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4:5 (2006), 639–644.
79. Harrison, S.A., Fecht, W., Brunt, E.M., et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49:1 (2009), 80–86.
80. Zein, C.O., Yerian, L.M., Gogate, P., et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatolgy 54:5 (2011), 1610–1619.
81. Van Wagner, L.B., Koppe, S.W., Brunt, E.M., et al. Pentoxyfylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 10:3 (2011), 277–286.
82. Lindor, K.D., Kowdley, K.V., Heathcote, E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39:3 (2004), 770–778.
83. Chalasani, N., Aljadhey, H., Kesterson, J., et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 128 (2004), 1287–1292.
84. Vuppalanchi, R., Teal, E., Chalasani, N., Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 329 (2005), 62–65.
85. Tziomalos, K., Athyros, V.G., Paschos, P., et al. Nonalcoholic fatty liver disease and statins. Metabolism 64:10 (2015), 1215–1223.